Rita P. Loudermilk

Rita P. Loudermilk

Auto-generated profile, based on publicly available information

Rita P. Loudermilk

ImmunoX Initiative, University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ACAlexis J. Combes
Alexis J. Combes
TCTristan Courau
Tristan Courau
NKNicholas F. Kuhn
Nicholas F. Kuhn
KHKenneth H. Hu
Kenneth H. Hu
ARArja Ray
Arja Ray
MKMatthew F. Krummel
Matthew F. Krummel

27 August 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JWJeffrey D. Whitman
Jeffrey D. Whitman
JHJoseph Hiatt
Joseph Hiatt
CMCody T. Mowery
Cody T. Mowery
BSBrian R. Shy
Brian R. Shy
RYRuby Yu
Ruby Yu
AMAlex Marson
Alex Marson

28 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ARAkshaya Ramesh
Akshaya Ramesh
RSRyan D. Schubert
Ryan D. Schubert
AGAriele L. Greenfield
Ariele L. Greenfield
RDRavi Dandekar
Ravi Dandekar
RLRita Loudermilk
Rita Loudermilk
MWMichael Wilson
Michael Wilson
Central nervous system B cells have several potential roles in multiple sclerosis (MS): secretors of proinflammatory cytokines and chemokines, presenters of autoantigens to T cells, producers of pathogenic antibodies, and reservoirs for viruses that trigger demyelination. To interrogate these roles, single-cell RNA sequencing (scRNA-Seq) was performed on paired cerebrospinal fluid (CSF) and blood from subjects with relapsing-remitting MS (RRMS; n = 12), other neurologic diseases (ONDs; n = 1), and healthy controls (HCs; n = 3). Single-cell immunoglobulin sequencing (scIg-Seq) was performed on a subset of these subjects and additional RRMS (n = 4), clinically isolated syndrome (n = 2), and OND (n = 2) subjects. Further, paired CSF and blood B cell subsets (RRMS; n = 7) were isolated using fluorescence activated cell sorting for bulk RNA sequencing (RNA-Seq). Independent analyses across technologies demonstrated that nuclear factor kappa B (NF-κB) and cholesterol biosynthesis pathways were activated, and specific cytokine and chemokine receptors were up-regulated in CSF memory B cells. Further, SMAD/TGF-β1 signaling was down-regulated in CSF plasmablasts/plasma cells. Clonally expanded, somatically hypermutated IgM+ and IgG1+ CSF B cells were associated with inflammation, blood–brain barrier breakdown, and intrathecal Ig synthesis. While we identified memory B cells and plasmablast/plasma cells with highly similar Ig heavy-chain sequences across MS subjects, similarities were also identified with ONDs and HCs. No viral transcripts, including from Epstein–Barr virus, were detected. Our findings support the hypothesis that in MS, CSF B cells are driven to an inflammatory and clonally expanded memory and plasmablast/plasma cell phenotype. Significance B cells serve as a key weapon against infectious diseases. They also contribute to multiple autoimmune diseases, including multiple sclerosis (MS) where depletion of B cells is a highly effective therapy. We describe a comprehensive profile of central nervous system (CNS)-specific transcriptional B cell phenotypes in MS at single-cell resolution with paired immune repertoires. We reveal a polyclonal immunoglobulin M (IgM) and IgG1 cerebrospinal fluid B cell expansion polarized toward an inflammatory, memory and plasmablast/plasma cell phenotype, with differential up-regulation of specific proinflammatory pathways. We did not find evidence that CNS B cells harbor a neurotropic virus. These data support the targeting of activated resident B cells in the CNS as a potentially effective strategy for control of treatment-resistant chronic disease.

1 May 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
ESEric Song
Eric Song
CBChristopher M. Bartley
Christopher M. Bartley
RCRyan D. Chow
Ryan D. Chow
TNThomas T. Ngo
Thomas T. Ngo
RJRuoyi Jiang
Ruoyi Jiang
SFShelli F. Farhadian
Shelli F. Farhadian
Individuals with coronavirus disease 2019 (COVID-19) frequently develop neurological symptoms, but the biological underpinnings of these phenomena are unknown. Through single-cell RNA sequencing (scRNA-seq) and cytokine analyses of cerebrospinal fluid (CSF) and blood from individuals with COVID-19 with neurological symptoms, we find compartmentalized, CNS-specific T cell activation and B cell responses. All affected individuals had CSF anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies whose target epitopes diverged from serum antibodies. In an animal model, we find that intrathecal SARS-CoV-2 antibodies are present only during brain infection and not elicited by pulmonary infection. We produced CSF-derived monoclonal antibodies from an individual with COVID-19 and found that these monoclonal antibodies (mAbs) target antiviral and antineural antigens, including one mAb that reacted to spike protein and neural tissue. CSF immunoglobulin G (IgG) from 5 of 7 patients showed antineural reactivity. This immune survey reveals evidence of a compartmentalized immune response in the CNS of individuals with COVID-19 and suggests a role of autoimmunity in neurologic sequelae of COVID-19.

22 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JSJoseph J. Sabatino
Joseph J. Sabatino
KMKristen Mittl
Kristen Mittl
WRWilliam M. Rowles
William M. Rowles
KMKira McPolin
Kira McPolin
JRJayant V. Rajan
Jayant V. Rajan
RBRiley Bove
Riley Bove
BACKGROUND: Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target humoral and cellular immunity. A comprehensive comparison of the effects of MS DMTs on SARS-CoV-2 vaccine–specific immunity is needed, including quantitative and functional B and T cell responses. METHODS: Spike-specific Ab and T cell responses were measured before and following SARS-CoV-2 vaccination in a cohort of 80 study participants, including healthy controls and patients with MS in 6 DMT groups: untreated and treated with glatiramer acetate (GA), dimethyl fumarate (DMF), natalizumab (NTZ), sphingosine-1-phosphate (S1P) receptor modulators, and anti-CD20 mAbs. Anti–spike-Ab responses were assessed by Luminex assay, VirScan, and pseudovirus neutralization. Spike-specific CD4 + and CD8 + T cell responses were characterized by activation-induced marker and cytokine expression and tetramer. RESULTS: Anti-spike IgG levels were similar between healthy control participants and patients with untreated MS and those receiving GA, DMF, or NTZ but were reduced in anti-CD20 mAb– and S1P-treated patients. Anti-spike seropositivity in anti-CD20 mAb–treated patients was correlated with CD19 + B cell levels and inversely correlated with cumulative treatment duration. Spike epitope reactivity and pseudovirus neutralization were reduced in anti-CD20 mAb– and S1P-treated patients. Spike-specific CD4 + and CD8 + T cell reactivity remained robust across all groups, except in S1P-treated patients, in whom postvaccine CD4 + T cell responses were attenuated. CONCLUSION: These findings from a large cohort of patients with MS exposed to a wide spectrum of MS immunotherapies have important implications for treatment-specific COVID-19 clinical guidelines. FUNDING: NIH grants 1K08NS107619, K08NS096117, R01AI159260, R01NS092835, R01AI131624, and R21NS108159; NMSS grants TA-1903-33713 and RG1701-26628; Westridge Foundation; Chan Zuckerberg Biohub; Maisin Foundation.

1 October 2020 in Cell Reports Medicine
Verified
Journal Article
Open access
CZColin R. Zamecnik
Colin R. Zamecnik
JRJayant V. Rajan
Jayant V. Rajan
KYKevin A. Yamauchi
Kevin A. Yamauchi
SMSabrina A. Mann
Sabrina A. Mann
RLRita P. Loudermilk
Rita P. Loudermilk
MWMichael Wilson
Michael Wilson
Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we use ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies nine candidate antigens, eight of which are derived from the two proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source.